FUNDAMENTALS |
MarketCap: |
2.90 mill
|
EPS: |
-0.160
|
P/E: |
-0.410
|
Earnings Date: |
May 20, 2024 |
SharesOutstanding: |
44.57 mill
|
Avg Daily Volume: |
0.0905 mill
|
RATINGS |
Rating CashFlow: |
Strong Sell
|
|
Return On Equity: |
Neutral
|
|
Return On Asset: |
Neutral
|
|
DE: |
Strong Sell
|
|
P/E: |
Strong Sell
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
Revenue | n/a | | n/a | n/a | n/a | |
Gr.Profit | n/a | | n/a | n/a | n/a | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.410 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-0.07x
|
Company: PE -0.410 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0580 - 0.0720
( +/- 10.77%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-09-18 | Hamilton John F | Buy | 15 000 | Stock Options |
2023-09-18 | Windham-bannister Susan Richards | Buy | 15 000 | Stock Options |
2023-09-18 | Patzer Eric | Buy | 15 000 | Stock Options |
2023-09-18 | Truong Vu | Buy | 30 000 | Stock Options |
2023-09-18 | Jafri Hasan | Buy | 20 000 | Stock Options |
INSIDER POWER |
79.41
|
Last
96 transactions |
Buy:
1 744 135 | Sell:
1 215 301 |
Forecast:
15:47 - $0.0640
Live Trading Signals (every 1 min)
Forecast
1: 14:17 - $0.0630
Forecast 2: 15:07 - $0.0650
Forecast 3: 15:47 - $0.0640
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
Volume Signals |
Price |
$0.0650 (0.00% )
|
Volume |
0.0244 mill
|
Avg. Vol. |
0.0905 mill
|
% of Avg. Vol |
26.92 %
|
Signal 1: |
|
Signal 2: |
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARDS
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.